Milestones
- Phase 2 results in NEJM (24.2% at 48 weeks)Jun 2023Complete.
- Obesity + knee arthritis trial headlineDec 2025Complete.
- Phase 3 headline: 28.3% at 80 weeks (top dose)21 May 2026Complete.
- Filing for obesity approvalNowCurrent milestone.
Most important updates
- 25d ago
- 12 Aug 2026
- 21 May 2026
Upcoming
- Q4 2026Retatrutide obesity NDA submission (next)
Physics limits
- The body defends its weightAs weight falls, hunger hormones rise and energy use drops, so loss plateaus after about a year. When treatment stops, most people regain much of it: in one trial, about two-thirds within a year.
- Part of the weight lost is muscleRoughly a quarter to a third of the weight lost on these drugs is lean mass, not fat. In older people that loss of muscle and bone can matter more than the weight itself.
- Glucagon is a double-edged signalGlucagon burns energy but also raises blood sugar and heart rate. Balancing it against the other two hormones sets a ceiling on how hard the drug can push without side effects.
How it works

One peptide, three hormones
Retatrutide switches on the GIP, GLP-1 and glucagon receptors at once, and lasts long enough for weekly shots.
Eat less
The GLP-1 and GIP signals act on the brain's appetite centres and slow the stomach, so people feel full sooner.
Spend more
The glucagon signal makes the liver burn fat and raises energy use, adding to weight loss and cutting liver fat.
Update log
Tue 15 Sep
- Major: PressTest
Wed 12 Aug
- Minor: PressRegulatory
Thu 21 May
- Major: PressTest
About Eli Lilly
Eli Lilly
Zepbound, obesity pill, retatrutide
US drugmaker that leads in obesity and diabetes drugs. Tirzepatide (Mounjaro, Zepbound) is among the world's best-selling drugs, its GLP-1 pill was approved in 2026, and retatrutide gave about 28% weight loss in Phase 3. It bought Verve (gene editing) in 2025.
- Became the first drugmaker worth about $1 trillion (Nov 2025), thanks to tirzepatide.
- Foundayo (orforglipron), a daily GLP-1 pill with no food or water rules, was FDA-approved for obesity on 1 Apr 2026.
- Retatrutide gave 28.3% average weight loss at 80 weeks on the top dose in Phase 3 (May 2026).
- Founded
- 1876150 yrs
- Headquarters
- United States
- Status
- Public
- Listed
- LLY (opens google.com)NYSE
- Valuation
- $1.1Tmarket capSep 2026
- Works in
- BiotechObesity & metabolism
- Coverage
- 4 programs · 18 updateslatest 25d agochecked 25 Sep
- People
- David A. Ricks (opens en.wikipedia.org)Chair and CEODaniel SkovronskyChief Scientific Officer

